参考文献：

[1] 袁丁,赵纪春,王家嵘,等.2018年美国血管外科学会(ASVS)腹主动脉瘤诊治临床实践指南解读[J].中国循证医学杂志,2018,18(12):1273-1280.

[2] Expert Panels on Vascular imaging and Interventional Radiology.ACR appropriateness criteria abdominal aortic aneurysm: interventional planning and follow-up[J].J Am Coll Radiol, 2018, 15: S2-S12.

[3] Bouri S, Shun-Shin M J, Cole G D, et al.Meta-analysis of secure randomised controlled trials of β-blockade to prevent perioperative death in non-cardiac surgery[J].Heart, 2014, 100(6): 456-464.

[4] Wijeysundera D N, Duncan D, Nkonde-Price C, et al.Perioperative beta blockade in noncardiac surgery: A systematic review for the 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines[J].J Am Coll Cardiol, 2014, 64(22): 2406-2425.(https://www.daowen.com)

[5] 王颖,顾慧,于鑫鑫,等.71例腹主动脉瘤的基线CT特征与病变进展的相关性[J].山东大学学报(医学版),2022,60(10):62-67.

[6] 付慧,周灿灿,李冬洁,等.腹主动脉瘤的研究进展:病理机制及动物模型[J].中国医学科学院学报,2022,44(3):516-520.

[7] 吴明炜,熊江.“ENGAGE”治疗腹主动脉瘤8年随访数据解读及展望[J].中国普通外科杂志,2022,31(6):713-716.